Efficacy of PD-1 blockade in tumors with MMR deficiency

open access

...As for the noncolorectal patients, the path toward development may have to follow traditional histology based clinical trials, however, this approach for multiple, rare diseases would be cumbersome and resource intensive. As we get more experience with various diseases, a more forward-thinking approach for drug development would allow targeting of mismatch repair deficiency across tumor types in a molecularly-targeted, tissue agnostic treatment strategy. Even if only 5% of cancers across the world were mismatch repair deficient, this would bring a new treatment option with prolonged benefit to many individual patients